0001062993-23-020922.txt : 20231115
0001062993-23-020922.hdr.sgml : 20231115
20231115164144
ACCESSION NUMBER: 0001062993-23-020922
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231113
FILED AS OF DATE: 20231115
DATE AS OF CHANGE: 20231115
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Singer Michael
CENTRAL INDEX KEY: 0002000122
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37798
FILM NUMBER: 231411139
MAIL ADDRESS:
STREET 1: C/O CARTESIAN THERAPEUTICS, INC.
STREET 2: 704 QUINCE ORCHARD RD
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cartesian Therapeutics, Inc.
CENTRAL INDEX KEY: 0001453687
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 65 GROVE STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-923-1400
MAIL ADDRESS:
STREET 1: 65 GROVE STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: SELECTA BIOSCIENCES INC
DATE OF NAME CHANGE: 20090109
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2023-11-13
0001453687
Cartesian Therapeutics, Inc.
RNAC
0002000122
Singer Michael
C/O CARTESIAN THERAPEUTICS, INC.
65 GROVE STREET
WATERTOWN
MA
02472
1
0
1
0
0
Common Stock
2023-11-13
4
A
0
110123
0
A
110123
D
Common Stock
2023-11-13
4
J
0
197663
0
A
197663
I
by trust
Common Stock
2023-11-13
4
J
0
29212
0
A
29212
I
by trust
Common Stock
2023-11-13
4
J
0
3670
0
A
3670
I
by trust
Common Stock
2023-11-13
4
J
0
49555
0
A
49555
I
as custodian
Common Stock
2023-11-13
4
J
0
49555
0
A
49555
I
as custodian
Common Stock
2023-11-13
4
J
0
7616
0
A
7616
I
by spouse
Series A Non-Voting Convertible Preferred Stock
2023-11-13
4
A
0
6304.559
A
Common Stock
6304559
6304.559
D
Series A Non-Voting Convertible Preferred Stock
2023-11-13
4
J
0
11316.263
A
Common Stock
11316263
11316.263
I
by trust
Series A Non-Voting Convertible Preferred Stock
2023-11-13
4
J
0
1672.389
A
Common Stock
1672389
1672.389
I
by trust
Series A Non-Voting Convertible Preferred Stock
2023-11-13
4
J
0
210.152
A
Common Stock
210152
210.152
I
by trust
Series A Non-Voting Convertible Preferred Stock
2023-11-13
4
J
0
2837.052
A
Common Stock
2837052
2837.052
I
as custodian
Series A Non-Voting Convertible Preferred Stock
2023-11-13
4
J
0
2837.052
A
Common Stock
2837052
2837.052
I
as custodian
Series A Non-Voting Convertible Preferred Stock
2023-11-13
4
J
0
436.066
A
Common Stock
436066
436.066
I
by spouse
On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger.
Shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the trust.
Shares are held in a trust for which the reporting person is a beneficiary. The reporting person is a trustee of the trust.
Shares are held in a trust for which the reporting person is a beneficiary. The reporting person's spouse is a trustee of the trust.
The shares are held for LS, the child of the reporting person, through a custodial account established pursuant to the Uniform Transfer to Minors Act ("UTMA") for which the reporting person serves as custodian.
The shares are held for SS, the child of the reporting person, through a custodial account established pursuant to the UTMA for which the reporting person serves as custodian.
Shares are held by the reporting person's spouse.
Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.
/s/ Michael Singer
2023-11-15